GigaGen Announces $1.5M NIH Grant Award for Development of Recombinant Intravenous Immunoglobulin


GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute of Allergy and Infectious Diseases (NIAID). The grant supports development of natural repertoire recombinant intravenous immunoglobulin (rIVIG) “hyperimmunes” against common pathogens for patients with primary immune deficiency (PID).

Read the full press release.